

RETRACTION NOTE

Open Access



Retraction Note: Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis

Jialiang Hu^{1,2†}, Wenjing Wang^{1†}, Chen Liu^{1,2}, Mengwei Li^{1,2}, Edouard Nice³ and Hanmei Xu^{1,2*}

Retraction Note: J Exp Clin Cancer Res
<https://doi.org/10.1186/s13046-019-1324-7>

The authors have retracted this article [1] because the bands shown in Fig. 5 panel D for GTP-RhoA/Control, GTP-RhoA/Sunitinib (2 and 64 nM) and GTP-RhoA/HM-3 (4.5 and 72 uM) are not data generated as part of this study. All authors agree to this retraction.

Author details

¹State Key Laboratory of Natural Medicines, Ministry of Education, China Pharmaceutical University, Nanjing 210009, People's Republic of China. ²The Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation of Jiangsu Province, Nanjing 211198, People's Republic of China. ³Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia.

Published online: 17 February 2020

Reference

1. Hu J, Wang W, Liu C, et al. Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis. *J Exp Clin Cancer Res*. 2019;38:381. <https://doi.org/10.1186/s13046-019-1324-7>.

The original article can be found online at <https://doi.org/10.1186/s13046-019-1324-7>

* Correspondence: 13913925346@126.com

[†]Jialiang Hu and Wenjing Wang contributed equally to this work.

¹State Key Laboratory of Natural Medicines, Ministry of Education, China Pharmaceutical University, Nanjing 210009, People's Republic of China

²The Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation of Jiangsu Province, Nanjing 211198, People's Republic of China

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.